Company News
PRESS RELEASE | March 15, 2023
Update From CEO Tony Pare
Preliminary 2022 financials, the status of US Food and Drug Administration (FDA) review, and a focus on European expansion. Read More
PRESS RELEASE | November 10, 2022
FDA De Novo Submission with Breakthrough Device Designation
BioPorto submitted an FDA De Novo application with Breakthrough Device Designation for an NGAL test to aid in identifying pediatric patients ≥ 3 months to < 22 years at risk of moderate to severe acute kidney injury. Read More
EVENT | November 2-6, 2022
See You Soon at ASN Kidney Week in Orlando
We are excited to see NGAL featured on the podium and in posters. Visit us at booth 2734 for the latest company and NGAL updates. Read More
PRESS RELEASE | June 28, 2022
BioPorto Achieves Targeted Enrollment in Clinical Study
This is the third part of a 3-part clinical study to support a US FDA De Novo submission for use of The NGAL Test in identifying patients under the age of 22 years at risk for acute kidney injury. Read More
PRESS RELEASE | June 20, 2022
BioPorto Appoints Dr. Prasad Devarajan as New Senior Medical Director
World-renowned pediatric nephrologist and NGAL expert Dr. Prasad Devarajan will join the BioPorto team effective July 1, 2022. CEO Tony Pare notes that “Dr. Devarajan’s unparalleled reputation, knowledge, and expertise will be a tremendous gain for BioPorto.” Read More
EVENT | June 15, 2022
Meet the Expert Session – 40th Vicenza Course on AKI & CRRT
Drs. Stuart Goldstein and Jean-Maxime Côté share their experiences implementing a renal biomarker into clinical practice from workflow modifications and training to the impact on patient care management and outcomes. More from the experts.
PRESENTATION | May 11, 2022
Strong Performance of The NGAL Test Drives Revenue Growth
CEO Tony Pare attributes BioPorto’s Q1 2022 17% growth to strong sales of The NGAL Test and ELISA kits. View the investor presentation at https://bit.ly/3Nb4no4
PRESS RELEASE | March 7, 2022
BioPorto A/S Announces Intention to Initiate a Rights Issue with Pre-emptive Subscription Rights for Existing Shareholders
Plus updates on the status of The NGAL Test clinical trials for De Novo application to the U.S. FDA; 2021 financial estimate and guidance for 2022. Press Release
EVENT | March 7-10, 2022
See You in San Diego at AKI & CRRT 2022
CEO Tony Pare is excited to connect with AKI researchers and clinicians in San Diego this week, reaffirming that there is a strong need to a kidney injury biomarker like NGAL. Hear from Tony
PRESENTATION | November 19, 2021
New Composition of the Management Board of BioPorto A/S
New CEO Anthony Pare and CFO Neil A. Goldman appointed; Per Mørch Eriksen to join as a member of the Board of Directors. Watch the video.